Is 'nearshoring', the preference among pharma and biotech to move operations to the domestic markets versus outsourcing ...

In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround ...

A federal judge in Houston has rejected the third attempt by J&J subsidiary Red River to settle lawsuits related to its ...

But while platform trials have the potential to be more effective and less expensive than traditional trials, challenges ...

US-based Johnson & Johnson (J&J) has announced that it will be investing $55bn in new US manufacturing facilities over the ...

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US government to add to vaccine ...

Total deal value of innovator drug licensing agreements involving Chinese biopharma licensors has risen 66% to $41.5 billion ...

With an increasing demand for NHS services, technology is being positioned as a critical tool in eliminating inefficiencies ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

Apollomics and LaunXP have signed an agreement to develop and commercialise the former’s c-Met inhibitor vebreltinib.

The FDA has approved AstraZeneca's Imfinzi with gemcitabine and cisplatin as neoadjuvant treatment in adults with MIBC.

The establishment of NHS England (NHSE) to undertake functions previously the responsibility of the then Department of Health ...